Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases

Upstream Bio Announces $200M Series B Financing to Advance UPB-101 for Allergic and Inflammatory Diseases

Source: 
Yahoo/Businesswire
snippet: 

Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced the completion of a $200 million Series B financing.